Pfizer Inc. has filed an amendment to its Schedule 13D with the United States Securities and Exchange Commission, detailing changes in its ownership stake in Haleon PLC. As of October 3, 2024, Pfizer beneficially owns 1,361,709,764 Ordinary Shares of Haleon PLC, which represents approximately 15.0% of the company's outstanding shares. This ownership includes both restricted American Depositary Shares and Ordinary Shares held by Pfizer's nominee. The filing follows a series of transactions, including the September 2024 Secondary Offering and the September 2024 Share Buyback, where Pfizer sold Ordinary Shares to Haleon PLC for approximately £230 million. The Share Buyback was concurrent with the Secondary Offering and closed on the same date. Pfizer entered into a share purchase deed with Haleon PLC in July 2024, which provided a...Show More

Pfizer Inc. has filed an amendment to its Schedule 13D with the United States Securities and Exchange Commission, detailing changes in its ownership stake in Haleon PLC. As of October 3, 2024, Pfizer beneficially owns 1,361,709,764 Ordinary Shares of Haleon PLC, which represents approximately 15.0% of the company's outstanding shares. This ownership includes both restricted American Depositary Shares and Ordinary Shares held by Pfizer's nominee. The filing follows a series of transactions, including the September 2024 Secondary Offering and the September 2024 Share Buyback, where Pfizer sold Ordinary Shares to Haleon PLC for approximately £230 million. The Share Buyback was concurrent with the Secondary Offering and closed on the same date. Pfizer entered into a share purchase deed with Haleon PLC in July 2024, which provided a framework for off-market purchases of Ordinary Shares from Pfizer. The amendment also outlines Pfizer's agreement with several financial institutions to manage the September 2024 Secondary Offering, which resulted in the sale of 640 million Ordinary Shares at a price of 380 pence per share. Pfizer has agreed to a 60-day lock-up period following the closing of the Secondary Offering, during which it will not sell any additional equity securities of Haleon PLC.